| __timestamp | Amphastar Pharmaceuticals, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 100244000 |
| Thursday, January 1, 2015 | 37065000 | 29674000 |
| Friday, January 1, 2016 | 41199000 | 14917000 |
| Sunday, January 1, 2017 | 43415000 | 14118000 |
| Monday, January 1, 2018 | 57564000 | 8737000 |
| Tuesday, January 1, 2019 | 68853000 | 6900000 |
| Wednesday, January 1, 2020 | 67229000 | 6248000 |
| Friday, January 1, 2021 | 60932000 | 12312000 |
| Saturday, January 1, 2022 | 74771000 | 19721000 |
| Sunday, January 1, 2023 | 73741000 | 31283000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, innovation is key. Amphastar Pharmaceuticals, Inc. and MannKind Corporation have been investing in research and development (R&D) to stay ahead. From 2014 to 2023, Amphastar consistently increased its R&D spending, peaking at approximately $74.8 million in 2022. This represents a growth of over 160% from its 2014 investment. In contrast, MannKind's R&D expenses saw a significant decline, dropping from a high of $100.2 million in 2014 to just $31.3 million in 2023, a decrease of nearly 69%.
Amphastar's commitment to innovation is evident in its steady increase in R&D investment, while MannKind's fluctuating expenses suggest a more volatile approach. This data highlights the strategic differences between the two companies in their pursuit of innovation, with Amphastar taking a more consistent path.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Summit Therapeutics Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Research and Development Expenses Breakdown: Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation
R&D Spending Showdown: Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds